Search "GLP-1 microdosing" this week and the pitch has quietly changed. It isn't about losing the last five pounds anymore, it's inflammation, energy, and aging slower, sold in a dose so small a doctor would barely call it one. The one real anti-aging study behind that claim, published this July, used the full weekly dose semaglutide actually ships in, on patients dealing with HIV-related fat and inflammation, not the fraction being marketed to you as the gentler version.
The dose in the study isn't the dose in the post
Cedars-Sinai's own obesity medicine team put a name to what they were seeing from patients this spring. "Microdosing is not a medical term," obesity medicine director Amanda Velazquez told the health system's own publication. It's a term wellness companies popularized and then define however suits them, often as a quarter of whatever dose a person happens to be on. Real prescriptions already range from a low starting amount up to a target maintenance dose, so there's no single number for a quarter of it to mean. Nobody has published human data on what a fraction of any of it actually does, whether it delivers a fraction of the benefit, all of it, or none.
The one real data point arrived this July in Nature Communications, from a team at UC San Diego. Semaglutide, given at its full prescribed weekly amount, not a fraction of it, appeared to slow biological aging on several epigenetic markers tied to inflammation and organ health, including a 9 percent slower pace on one widely used clock. The lead author was careful not to oversell it. "We are not saying that semaglutide reverses aging," he said. "What we are seeing is a signal." Every participant had HIV-associated lipohypertrophy, not a general midlife audience.
If the aging angle is what actually drew you in, the evidence you're leaning on is tied to the full prescribed dose, not the fractional kind. A smaller dose can also clear your system faster than intended, so the side effects you were trying to avoid by going small show up anyway, minus the steady blood levels the study was actually built on. Compounded fractional doses add a second problem, since nobody's checking potency or purity on a dose you're dividing yourself.
The market didn't panic, even though the headlines made it sound like it should
Eli Lilly's six federal lawsuits against retatrutide sellers made last week's issue. Since then, a handful of vendors have quietly pulled their own listings, and if yours went quiet, that's probably why. None of the four companies Lilly actually named are ones you'd find in our directory. A delisting isn't a recall either. Nobody's saying the vial you already bought is unsafe, and nobody's banned the compound, because it was never approved for consumer sale to begin with. Here's the background on the lawsuits, and the vendor count held steady all month, including the week the lawsuits hit.
Check the live price yourself instead of reading the headline. It's been falling since late July, not spiking, so there's no data-backed reason to panic-buy the first new listing you find.
A delisting is one company deciding its own risk tolerance changed. It isn't the market deciding anything.
Reply if you want the semaglutide-versus-tirzepatide numbers pulled apart the same way next. Until next Saturday.